68Ga-DOTATATE PET before Lutathera (177Lu-DOTATATE)
Before starting the neuroendocrine tumour treatment Lutathera, patients get a somatostatin-receptor PET scan to confirm the tumour actually has the right target for the drug to lock onto. Lutathera's approval and use are built around this scan-first rule.
Overview
Lutathera (177Lu-dotatate) is FDA-approved for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, and its own label states that eligibility in the pivotal programme required 'confirmed presence of somatostatin receptors on all lesions,' historically demonstrated with OctreoScan (111In-pentetreotide) uptake at least equal to normal liver, and now more commonly with PET agents such as 68Ga-DOTATATE, 68Ga-DOTATOC or 64Cu-DOTATATE, which have largely replaced OctreoScan because of higher sensitivity and better lesion detectability. Lesions with tracer uptake less than liver activity are considered somatostatin-receptor-negative and are not expected to respond to Lutathera; patients with significant somatostatin-receptor-negative (and, where available, FDG-positive) disease are generally excluded from treatment because such discordant lesions predict poor response to PRRT.
This is a drug-specific instance of the broader diagnostic-therapeutic 'theranostic' pairing between somatostatin-receptor PET and peptide receptor radionuclide therapy: the same molecular target (SSTR2) is imaged with a gallium-68- or copper-64-labelled diagnostic tracer and then treated with the lutetium-177-labelled therapeutic analogue, so the scan used for staging doubles as the biomarker test that selects patients for, and later monitors response to, Lutathera. SNMMI/EANM and society guidance recommend repeat somatostatin-receptor PET roughly 3-6 months after completing PRRT to assess response.
Eligibility based on receptor imaging (Krenning score equivalent, uptake greater than liver) sits alongside other selection criteria in the Lutathera label and NET treatment guidelines, including Ki-67 index, performance status, renal function and prior PRRT exposure. This record is specific to the Lutathera-DOTATATE PET pairing and is distinct from the generic sstr-pet-to-prrt technology-level pairing already in this graph, which covers somatostatin receptor PET's relationship to PRRT as a modality rather than the specific FDA-labelled drug requirement.
Similar pages
not linked directly; found by shared links- TermKrenning score
Shares Indium-111, Gallium-68 DOTATATE (and Cu-64 DOTATATE), Copper-64, Somatostatin receptor PET (68Ga/64Cu-DOTATATE).
- Key paperResults and adverse events of personalised peptide receptor radionuclide therapy in 1048 patients with neuroendocrine neoplasms
Shares Richard P. Baum, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate, Neuroendocrine tumours and the tag neuroendocrine tumours.
- TermTheranostic pair
Shares SSTR PET → PRRT, Gallium-68 DOTATATE (and Cu-64 DOTATATE), Copper-64, Lutetium-177 dotatate and the tag theranostics.
- AgentLutetium-177 dotatate (radioligand equivalent)
Shares Somatostatin receptor 2, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate, Neuroendocrine tumours and the tag neuroendocrine tumours.
- Key paperHealth-related quality of life in the NETTER-1 trial of 177Lu-Dotatate
Shares Richard P. Baum, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate, Lutetium-177 and the tag neuroendocrine tumours.
- TermPRRT (peptide receptor radionuclide therapy)
Shares Gallium-68 DOTATATE (and Cu-64 DOTATATE), Copper-64, Somatostatin receptor 2, Peptide receptor radionuclide therapy (PRRT).
- PairingPRRT (177Lu-DOTATATE) with capecitabine and temozolomide (CAPTEM)
Shares Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate, Neuroendocrine tumours, Lutetium-177 and the tag neuroendocrine tumours.
- AgentGallium-68 edotreotide (DOTATOC)
Shares Gallium-68 DOTATATE (and Cu-64 DOTATATE), Copper-64, Somatostatin receptor PET (68Ga/64Cu-DOTATATE), Somatostatin receptor 2.